Company Overview
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Why Investors Should Care
Generates a return on equity of 18.8%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 18.6%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -94.25% |
| 6 Months: | -9.79% |
| 3 Months: | +6.00% |
| 1 Month: | +4.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 96.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MENS Jyong Biotech Ltd. PHARMA | 2.12 | -35.33 | $157.38M | 0.00% | 18.58% | 18.75% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 2.83M | 2.80M | 2.06M | 2.61M |
| Operating Income | - | -2.83M | -2.80M | -2.06M | -2.61M |
| EBITDA | - | -5.74M | -3.52M | -1.86M | -2.03M |
| Interest Expense | - | 765.00K | 757.00K | 1.03M | 2.54M |
| Pretax Income | - | -6.63M | -4.40M | -3.02M | -4.67M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -6.63M | -4.40M | -3.02M | -4.67M |
| Diluted EPS | -0.06 | -0.09 | -0.06 | -0.04 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 8.74M | 8.25M | 6.37M | 20.78M |
| Current Assets | - | 2.46M | 1.84M | 206.00K | 15.54M |
| Cash & Equivalents | - | 718.00K | 177.00K | 98.00K | 1.18M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | 0 | 13.51M |
| Total Liabilities | - | 38.38M | 42.32M | 42.88M | 45.68M |
| Current Liabilities | - | 12.91M | 14.26M | 12.13M | 34.81M |
| Long Term Debt | - | 6.32M | 8.52M | 10.68M | 10.16M |
| Total Debt | - | 14.25M | 16.69M | 18.14M | 18.55M |
| Total Equity | - | -29.63M | -34.07M | -36.52M | -24.91M |
| Shares Outstanding | - | 76.03M | 76.03M | 76.03M | 76.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.97M | -2.60M | -3.62M | -3.04M |
| Investing Cash Flow | - | 1.39M | 95.00K | 0 | -13.51M |
| Financing Cash Flow | - | 3.33M | 2.03M | 1.99M | 17.63M |
| Capital Expenditure | -137.00K | -246.00K | - | - | - |
| Free Cash Flow | - | -3.22M | -2.60M | -3.62M | -3.04M |
| Net Change in Cash | - | 1.75M | -478.00K | -1.63M | 1.08M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 22.4% | 12.9% | 8.3% | 18.8% |
| ROCE % | - | 68.0% | 46.5% | 35.7% | 18.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 0.34% | 260.32K | $536.25K |
| 2 | Geode Capital Management, LLC | 0.09% | 68.88K | $141.90K |
| 3 | HRT Financial LP | 0.07% | 50.42K | $103.87K |
| 4 | Xtx Topco Ltd | 0.04% | 29.07K | $59.88K |
| 5 | Renaissance Technologies, LLC | 0.03% | 22.90K | $47.17K |
| 6 | China Universal Asset Management Co., Ltd. | 0.02% | 12.10K | $24.93K |
| 7 | State of Wyoming | 0.01% | 11.21K | $23.09K |
| 8 | JPMORGAN CHASE & CO | 0.01% | 5.38K | $11.08K |
| 9 | Morgan Stanley | 0.01% | 6.11K | $12.59K |
| 10 | Barclays Plc | 0.01% | 5.93K | $12.22K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MENS
A plant-based drug developer will join a two-language online investor event Sept. 6 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQVmMwMGtMOXk4aGZteXpJZkpMb21nUzFoc2NuNjlncnpYV25VRFIydURiaHVvNzVoQXJzcnJWMV9tR0JGa21xU2dKamdLNksycVFVdzR6bXM5UVJfLVdSNHVidGp6eVY2ZFpXdC0tdlVwcXNFTFFyLWZOc0d1VmxGcU1PZHFhdmpaN3puRX…
Luke Stock Earns Big Ten Men's Golfer of the Week Award - USC Athletics
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPaXJ0MGJNR3BpRXhYSDdtS2FrbjY4ZWJrMXExZE5OcHVKaTJreVRCendPcHFEb0hyUUtDLWZaRXZIeTQxd2puS0JyYWQ4aU1ZdUZ1QWZwdWlBeUdvbGdTVWRZemdnOGdjTTB4NU1WcDc2MGtKR1Z2Y2lETlBLM3Btc1JBdXR4ZmxSU3hFb0…
2026-27 Men's Golf Schedule Now Available - Columbia University Athletics
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOdTZKUXJuUlZJQ0wwd0lRcndNLTF4bUM1YjBldWQ2SFA0UlFlNG9vZzJoNkx0T0o1VXRKX0xhWmJWOGNuTUI3UXJYVXA2SXFXZC1raEpiSnh3Q0VUTjhDdG1TSk9EOGIyWk9zZWZFMzRSNzNhQVNLVmtoQ2RWMl96T2NUTldGdXB3dUw4UT…
Three Cards Earn All-ACC Academic Honors - gocards.com
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPenhUelY1ZTRaNkE5eU9XcDVqRmwyXzQ3a3RHMnNjN0pDU3R6TTA4dTRoV1BEWTdZNnhLTV9DWlUxclF0Q3Q5NUEtVVpvWjltNVpIRTFBZ2pVc2V5ZVJvQ3BpM05HalF4WW1lS3VZOHJGZGtSNVFqVzdDd0hTeXF0X2sxNnB0bUx5MUZV?o…
Jyong Biotech Ltd. Ordinary Shares (NASDAQ: MENS) Share Price, MENS Stock News, MENS Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFA2bFcybEZtNTNQWlAyM0E0V280RllDblRBWHJ3UWtzc3RMdkpVcnAxSnBTZzdVYndIUVJCMFR0cElUbkRWSXdZR3dEZVpJcnRPX1VXWEFR?oc=5" target="_blank">Jyong Biotech Ltd. Ordinary Shares (NASDAQ: MENS) S…
MENS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5KLWJzQXY0MnAtcjlqRWlrYzVxTDNmT3RJaUVQLUxkdG9MWlF0OUJaeTJ2MUVWZmxoOFBCTmtyRW9PX3RnMHc?oc=5" target="_blank">MENS</a> <font color="#6f6f6f">Finviz</font>…
MENS — Frequently Asked Questions
What is the current share price of Jyong Biotech Ltd. (MENS)?
As of 2026-09-19 21:16 PDT, Jyong Biotech Ltd. (MENS) trades at $2.12 on NasdaqGM. Its 52-week range is $1.46 to $65.62.
What is the market capitalisation of MENS?
Jyong Biotech Ltd. (MENS) has a market capitalisation of $157.38M on NasdaqGM.
What is the P/E ratio of MENS?
MENS trades at a trailing price-to-earnings (P/E) ratio of -35.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -6.13.
What is the return on equity (ROE) of MENS?
MENS has a return on equity (ROE) of 18.75%. Its return on capital employed (ROCE) is 18.58%.
Is MENS a good stock to buy?
This page provides a data-driven analysis of Jyong Biotech Ltd. (MENS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.